A Phase 3 interventional study of Idelalisib and Bendamustine in Chronic Lymphocytic Leukemia, sponsored by Gilead Sciences. Terminated at 91 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-19.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 1 under way, none of them phase 3. idelalisib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 3rd largest by enrollment, is one of 4 that started in 2014, is one of 8 in phase 3, and was the 14th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →1 of the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Australia, Austria and 14 more countries
Ages 18+
By country, each count listing its studies:
idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 8 · Phase 4 1
First in 2008; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 311 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 102 across the 25 interventional studies. Of the 22 that completed or were terminated, 21 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 25 have an industry lead sponsor. The 7 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
36 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gilead Sciences: none open now, none under way, none of them phase 3. Of 32 finished, 22 (69%) have results posted.
Among the 36 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gilead Sciences, this one is the 4th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2014, is one of 9 in phase 3, and was the 26th registered.
Gilead Sciences’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 36 in Leukemia, Lymphocytic, Chronic, B-Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the progression-free survival in participants with previously untreated chronic lymphocytic leukemia (CLL) who would otherwise be suitable for bendamustine and rituximab treatment as standard of care.
An increased rate of deaths and serious adverse events (SAEs) among participants with front-line CLL and early-line indolent non-Hodgkin lymphoma (iNHL) treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated this study in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA).
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive idelalisib for 96 weeks plus bendamustine+rituximab for 21 weeks.
Drug: Idelalisib · Drug: Bendamustine · Drug: Rituximab
Participants will receive placebo to match idelalisib for 96 weeks plus bendamustine+rituximab for 21 weeks.
Drug: Bendamustine · Drug: Rituximab · Drug: Placebo
150 mg tablet administered orally twice daily
Also known as: Zydelig®, GS-1101, CAL-101
Administered intravenously at a starting dose of 90 mg/m\^2 for up to 6 cycles. Dosing will be based on mg/m\^2 of body surface area.
Single-use vials administered intravenously weekly starting at 375 mg/m\^2 on Day 1 (Week 0) and 500 mg/m\^2 thereafter for a total of 6 infusions
Placebo to match idelalisib administered orally twice daily
Progression-Free Survival
Progression-free survival (PFS) is defined as the interval from randomization to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria, excluding lymphocytosis alone. PFS was to be assessed by an independent review committee (IRC).
Time frame: Up to 22 months
Overall Response Rate
Overall response rate (ORR) is defined as the proportion of participants who achieve a confirmed complete or partial response. ORR was to be assessed by an IRC.
Time frame: Up to 22 months
Nodal Response Rate
Nodal response rate is defined as the proportion of participants who achieve a 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions. Nodal response rate was to be assessed by an IRC.
Time frame: Up to 22 months
Complete Response Rate
Complete response rate is defined as the proportion of participants who achieve a confirmed complete response. Complete response rate was to be assessed by an IRC.
Time frame: Up to 22 months
Overall Survival
Overall survival is defined as the interval from randomization to death from any cause. Overall survival was to be assessed by an IRC.
Time frame: Up to 22 months
Minimal Residual Disease Negativity Rate at Week 36
Minimal residual disease (MRD) negativity rate is defined as the proportion of participants with MRD \< 10\^-4 assessed by flow cytometry in bone marrow at Week 36 after therapy initiation or at least 12 weeks after the last dose of rituximab or bendamustine (whichever is later) for participants receiving the final dose of rituximab after the original scheduled date. MRD negativity rate was to be assessed by an IRC.
Time frame: Up to 22 months
Participants were enrolled at study sites in the North America, Australia, and Europe. The first participant was screened on 05 February 2014. The last study visit occurred on 16 June 2016.
| Milestone | Idelalisib+Bendamustine+Rituximab | Placebo+Bendamustine+Rituximab |
|---|---|---|
| Started | 157 | 154 |
| Completed | 13 | 21 |
| Not completed | 144 | 133 |
| Withdrew: Study terminated by sponsor | 116 | 122 |
| Withdrew: Withdrew consent | 17 | 6 |
| Withdrew: Investigator's discretion | 8 | 3 |
| Withdrew: Non-compliance with study drug | 3 | 2 |
Progression-free survival (PFS) is defined as the interval from randomization to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria, excluding lymphocytosis alone. PFS was to be assessed by an independent review committee (IRC).
| months | Idelalisib+Bendamustine+Rituximab | Placebo+Bendamustine+Rituximab |
|---|---|---|
| Progression-Free Survival | NA (19.3 to NA) | NA (19.6 to NA) |
Overall response rate (ORR) is defined as the proportion of participants who achieve a confirmed complete or partial response. ORR was to be assessed by an IRC.
No measurements were reported for this outcome.
Nodal response rate is defined as the proportion of participants who achieve a 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions. Nodal response rate was to be assessed by an IRC.
No measurements were reported for this outcome.
Complete response rate is defined as the proportion of participants who achieve a confirmed complete response. Complete response rate was to be assessed by an IRC.
No measurements were reported for this outcome.
Overall survival is defined as the interval from randomization to death from any cause. Overall survival was to be assessed by an IRC.
No measurements were reported for this outcome.
Minimal residual disease (MRD) negativity rate is defined as the proportion of participants with MRD \< 10\^-4 assessed by flow cytometry in bone marrow at Week 36 after therapy initiation or at least 12 weeks after the last dose of rituximab or bendamustine (whichever is later) for participants receiving the final dose of rituximab after the original scheduled date. MRD negativity rate was to be assessed by an IRC.
No measurements were reported for this outcome.
Collected over Up to 22 months plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Idelalisib+Bendamustine+Rituximab | — | 113/156 (72.4%) | 154/156 (98.7%) |
| Placebo+Bendamustine+Rituximab | — | 68/154 (44.2%) | 150/154 (97.4%) |
| Event | Idelalisib+Bendamustine+Rituximab | Placebo+Bendamustine+Rituximab |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 29/156 | 16/154 |
| PyrexiaGeneral disorders | 26/156 | 19/154 |
| PneumoniaInfections and infestations | 11/156 | 6/154 |
| SepsisInfections and infestations | 9/156 | 2/154 |
| AnaemiaBlood and lymphatic system disorders | 8/156 | 2/154 |
| NeutropeniaBlood and lymphatic system disorders | 7/156 | 1/154 |
| DiarrhoeaGastrointestinal disorders | 6/156 | 1/154 |
| Neutropenic sepsisInfections and infestations | 5/156 | 1/154 |
| Tumour lysis syndromeMetabolism and nutrition disorders | 5/156 | 4/154 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 5/156 | 3/154 |
| Event | Idelalisib+Bendamustine+Rituximab | Placebo+Bendamustine+Rituximab |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 84/156 | 90/154 |
| PyrexiaGeneral disorders | 71/156 | 38/154 |
| NauseaGastrointestinal disorders | 61/156 | 63/154 |
| DiarrhoeaGastrointestinal disorders | 63/156 | 46/154 |
| RashSkin and subcutaneous tissue disorders | 63/156 | 34/154 |
| FatigueGeneral disorders | 43/156 | 44/154 |
| AnaemiaBlood and lymphatic system disorders | 40/156 | 29/154 |
| VomitingGastrointestinal disorders | 37/156 | 23/154 |
| ConstipationGastrointestinal disorders | 26/156 | 34/154 |
| CoughRespiratory, thoracic and mediastinal disorders | 34/156 | 29/154 |
Intent-to-Treat (ITT) Analysis Set: who were randomized regardless of whether subjects received any study drug(s), or received a different regimen from the regimen to which they were randomized.
| Age, Continuous(years) | Idelalisib+Bendamustine+Rituximab | Placebo+Bendamustine+Rituximab | Total |
|---|---|---|---|
| Mean | 64 ± 8.7 | 63 ± 10.0 | 64 ± 9.4 |
| Sex: Female, Male(Participants) | Idelalisib+Bendamustine+Rituximab | Placebo+Bendamustine+Rituximab | Total |
|---|---|---|---|
| Female | 57 | 48 | 105 |
| Male | 100 | 106 | 206 |
| Race/Ethnicity, Customized(Participants) | Idelalisib+Bendamustine+Rituximab | Placebo+Bendamustine+Rituximab | Total |
|---|---|---|---|
| Asian | 1 | 0 | 1 |
| Black or African American | 1 | 1 | 2 |
| White | 152 | 150 | 302 |
| Other | 3 | 1 | 4 |
| Not Permitted | 0 | 2 | 2 |
| Race/Ethnicity, Customized(Participants) | Idelalisib+Bendamustine+Rituximab | Placebo+Bendamustine+Rituximab | Total |
|---|---|---|---|
| Hispanic or Latino | 11 | 2 | 13 |
| Not Hispanic or Latino | 146 | 149 | 295 |
| Not Permitted | 0 | 3 | 3 |
| Region of Enrollment(participants) | Idelalisib+Bendamustine+Rituximab | Placebo+Bendamustine+Rituximab | Total |
|---|---|---|---|
| Romania | 4 | 1 | 5 |
| Hungary | 24 | 21 | 45 |
| United States | 35 | 25 | 60 |
| United Kingdom | 7 | 13 | 20 |
| Spain | 19 | 15 | 34 |
| Canada | 11 | 8 | 19 |
| Czech Republic | 10 | 17 | 27 |
| Belgium | 3 | 3 | 6 |
| Poland | 15 | 18 | 33 |
| Italy | 5 | 3 | 8 |
| Australia | 15 | 19 | 34 |
| France | 4 | 5 | 9 |
| Croatia | 5 | 6 | 11 |
| Rai Stage at Screening(Participants) | Idelalisib+Bendamustine+Rituximab | Placebo+Bendamustine+Rituximab | Total |
|---|---|---|---|
| Stage I | 28 | 30 | 58 |
| Stage II | 66 | 58 | 124 |
| Stage III | 25 | 32 | 57 |
| Stage IV | 38 | 34 | 72 |
| IgHV Mutation(Participants) | Idelalisib+Bendamustine+Rituximab | Placebo+Bendamustine+Rituximab | Total |
|---|---|---|---|
| Mutated | 54 | 54 | 108 |
| Unmutated | 102 | 100 | 202 |
| Missing | 1 | 0 | 1 |
| 17p Deletion in CLL Cells(Participants) | Idelalisib+Bendamustine+Rituximab | Placebo+Bendamustine+Rituximab | Total |
|---|---|---|---|
| Absent | 146 | 145 | 291 |
| Present | 10 | 9 | 19 |
| Missing | 1 | 0 | 1 |
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
No publications or documents are linked to this record.
Ran from Feb 2014 to primary completion in May 2016, 27 months.
Results were first posted in Oct 2017, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Idelalisib
Leukemia, Lymphocytic, Chronic, B-Cell →